Skip to main content
SpringerLink
Log in

Antivirals for Influenza: Novel Agents and Approaches

  • Conference paper
National Institute of Allergy and Infectious Diseases, NIH

Part of the book series: Infectious Disease ((ID))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Advisory Committee on Immunization Practices, Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA (2006) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55:1–42

    PubMed  Google Scholar 

  2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M, (2006) Safety and immunogenicity of an inactivated subvi-rion influenza A (H5N1) vaccine. N Engl J Med 354:1343–1351.

    Article  PubMed  CAS  Google Scholar 

  3. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368:991–997.

    Article  PubMed  CAS  Google Scholar 

  4. Leroux-Rocls I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster J-M, Leroux-Roels G (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580–589.

    Article  CAS  Google Scholar 

  5. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657–1664.

    Article  PubMed  CAS  Google Scholar 

  6. World Health Organization (2006) WHO Rapid Advice Guidelines on Pharmacological management of humans infected with avian influenza A (H5N1) virus. Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html.

  7. Hayden F (2004) Pandemic influenza—is an antiviral response realistic? Ped Infect Dis J 23:S262–S269.

    Article  Google Scholar 

  8. Longini IM Jr Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME (2005) Containing pandemic influenza at the source. Science 309:1083–1087.

    Article  PubMed  CAS  Google Scholar 

  9. Longini IM Jr Halloran ME, Nizam A, Yang Y (2004) Containing pandemic influenza with antiviral agents. Am J Epidemiol 159:623–633.

    Article  PubMed  Google Scholar 

  10. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS (2006) Strategies for mitigating an influenza pandemic. Nature 442:448–452.

    Article  PubMed  CAS  Google Scholar 

  11. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Lamsirithaworn S, Burke DS (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437:209–214.

    Article  PubMed  CAS  Google Scholar 

  12. Hayden FG, Aoki FY (2005) Amantadine, rimantadine, and relateds agents. In Antimicrobial Therapy and vaccines (Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds.), pp. 705–729, ESun Technologies, LLC, Pittsburg, PA.

    Google Scholar 

  13. Hayden FG, Aoki FY (2005) Influenza neuraminidase inhibitors. In Antimicrobial therapy and vaccines (Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds.), pp. 773–789. ESun Technologies, LLC, Pittsburg, PA.

    Google Scholar 

  14. Wang C, Takeuchi K, Pinto LH, Lamb RA (1993) Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 67:5585–5594.

    PubMed  CAS  Google Scholar 

  15. Martin K, Helenius A (1991) Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 67:117–130.

    Article  PubMed  CAS  Google Scholar 

  16. Hay AJ (1996) Amantadine and rimantadine—Mechanisms. In Antiviral Drug Resistance (Richman DD, ed.), pp. 43–58. John Wiley & Sons Ltd, New York.

    Google Scholar 

  17. Hayden FG (2006) Antivirals for influenza: Historical perspectives and lessons learned. Antiviral Res 71:372–378.

    Article  PubMed  CAS  Google Scholar 

  18. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Ada-mantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894.

    Article  PubMed  CAS  Google Scholar 

  19. WHO (2007) Clinical management of human infection with avain influenza A (H5N1) virus. WHO.int.website. http://www.who.int/csr/disease/avain_influenza/guidelines/clinicalmanage07/en/index.html

  20. Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–1373.

    Article  PubMed  CAS  Google Scholar 

  21. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Parr D, Huson L, Ward P, Mills RG (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336–1343.

    Article  PubMed  CAS  Google Scholar 

  22. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts R, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA 282:1240–1246.

    Article  PubMed  CAS  Google Scholar 

  23. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667–1672.

    Article  PubMed  CAS  Google Scholar 

  24. Hayden FG, Gubareva LV, Monto AS, Klein T, Elliott M, Hammond J, Sharp S, Ossi M (2000) Inhaled zanamivir for preventing influenza in families. N Engl J Med 343:1282–1289.

    Article  PubMed  CAS  Google Scholar 

  25. Monto AS, Robinson DP, Herlocher L, Hinson JM Jr, Elliott M, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults. JAMA 281:31–36.

    Article  Google Scholar 

  26. Nordstrom BL, Sung I, Suter P, Szneke P (2005) Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 21:761–768.

    Article  PubMed  CAS  Google Scholar 

  27. Nordstrom BL, Zhu S, Smith JR (2005) Reduction of influenza complications following oseltamivir use[abstract S18-2]. In Proceedings and abstracts of the Second European Influeza Conference (St. Julian' s, Malta). European Scientific Working Group on Influenza, St. Julian' s, Malta

    Google Scholar 

  28. Kaiser L, Keene ON, Hammond J, Elliott M, Hayden FG (2000) Impact of zanamivir on antibiotics use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 160:3234–3240.

    Article  PubMed  CAS  Google Scholar 

  29. Lee N, Chan P, Choi KW, Lui G, Wong B, Cockram CS, Hui DSC, Lai R, Tang JW, Sung JJY (2007) Factors associated with early hospital discharge of adult influenza patients. Antiviral Therapy 12:501–508.

    PubMed  Google Scholar 

  30. McGeer A, Green K, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, Low D. (2007) Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada. Clin Infect Dis 45:1568–1575

    Article  PubMed  Google Scholar 

  31. Monto AS, Kimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50:2395–2402.

    Article  PubMed  CAS  Google Scholar 

  32. NISN (2007) Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons. Weekly Epidemiological Record 82:149–150.

    Google Scholar 

  33. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F, Zambon M (2003) Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47:2264–2272.

    Article  PubMed  CAS  Google Scholar 

  34. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523–531.

    Article  PubMed  CAS  Google Scholar 

  35. Treanor JJ, Hayden FG, Vrooman PS, Barbarash RA, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 283:1016–1024.

    Article  PubMed  CAS  Google Scholar 

  36. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765.

    Article  PubMed  CAS  Google Scholar 

  37. Yen HL, Monto AS, Webster RG, Govorkova EA (2005) Virulence may determine the necessary duration and dosage of osel-tamivir treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in mice. J Infect Dis 192:665–672.

    Article  PubMed  CAS  Google Scholar 

  38. The Writing Committee of the World Health Organization Consultation on Human Influenza (2005) Avian influenza A (H5N1) infection in Humans. N Engl J Med 353:1374–1385

    Article  Google Scholar 

  39. Jong M, de Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau N, Cam BV, Qui PT, Ha DQ, Guan Y, Peiris JS, Hien T T Farrar J (2005) Oseltamivir resistance during treatment of influenza H5N1. N Engl J Med 353:2667–2672.

    Article  PubMed  Google Scholar 

  40. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KHL, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y (2005) Avian flu: Isolation of drug-resistant H5N1 virus. Nature 437:1108.

    Article  PubMed  CAS  Google Scholar 

  41. Smee DF, Bailey KW, Morrison A, Sidwell RW (2002) Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48:88–93.

    Article  PubMed  CAS  Google Scholar 

  42. Madren LK, Shipman C Jr Hayden FG (1995) In vitro inhibitory effects of combinations of anti-influenza agents. Antivir Chem Chemother 6:109–113.

    CAS  Google Scholar 

  43. Hayden FG (1996) Combination antiviral therapy for respiratory virus infections. Antivir Res 29:45–48.

    Article  PubMed  CAS  Google Scholar 

  44. Smee D, Wong MH, Bailey KW, Sidwell RW (2006) Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A(H1N1) and B viruses. Antivir Chem Chemother 17:185–192.

    PubMed  CAS  Google Scholar 

  45. De Clercq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5:1015–1025.

    Article  PubMed  CAS  Google Scholar 

  46. Ryan DM, Ticehurst J, Dempsey MH, Penn CR (1994) Inhibition of influenza virus replication in mice by GG167 (4-gua-nidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 38:2270–2275.

    PubMed  CAS  Google Scholar 

  47. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 337:874–879.

    Article  PubMed  CAS  Google Scholar 

  48. Kaiser L, Henry D, Flack N, Keene O, Hayden FG (2000) Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 30:587–589.

    Article  PubMed  CAS  Google Scholar 

  49. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG (2001) Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45:2723–2732.

    Article  PubMed  CAS  Google Scholar 

  50. McKimm-Breschkin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors—a review. Antivir Res 47:1–17.

    Article  PubMed  CAS  Google Scholar 

  51. Gubareva LV, Matrosovich MN, Brenner MK, Bethell R, Webster RG (1998) Evidence for zanamivir resistance in an immuno-compromised child infected with influenza B virus. J Infect Dis 178:1257–1262.

    Article  PubMed  CAS  Google Scholar 

  52. Jackson D, Barclay W, Zurcher T (2005) Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55:162–169.

    Article  PubMed  CAS  Google Scholar 

  53. Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49:4515–4520.

    Article  PubMed  CAS  Google Scholar 

  54. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, Hayden FG (2003) Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 41:742–750.

    Article  PubMed  CAS  Google Scholar 

  55. Elliott M (2001) Zanamivir: from drug design to the clinic. Philos Trans R Soc Lond B Biol Sci 356:1885–1893.

    Article  PubMed  CAS  Google Scholar 

  56. Cass L, Efthymiopoulos C, Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36:1–11.

    Article  PubMed  CAS  Google Scholar 

  57. Roche Laboratories, Inc. (2007) Tamiflu[product insert]. Available at: http://www.rocheusa.com/products/tamiflu/pi.pdf.

  58. Calfee DP, Peng AW, Cass L, Lobo M, Hayden FG (1999) Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 43:1616–1620.

    PubMed  CAS  Google Scholar 

  59. Young D, Fowler C, Bush K (2001) RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc Lond B Biol Sci 356:1905–1913.

    Article  PubMed  CAS  Google Scholar 

  60. Gubareva LV, Webster RG, Hayden FG (2001). Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403–3408.

    Article  PubMed  CAS  Google Scholar 

  61. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW (2001) Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza activities. Antimicrob Agents Chemother 45(3): 743–748.

    Article  PubMed  CAS  Google Scholar 

  62. Bantia S, Parker CD, Ananth SL, Horn LL, Andries K, Chand P, Kotian PL, Dehghani A, El-Kattan Y, Lin T, Hutchison TL, Montgomery JA, Kellog DL, Babu YS (2001) Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 45:1162–1167.

    Article  PubMed  CAS  Google Scholar 

  63. Sidwell RW, Smee DF (2000) In vitro and in vivo assay systems for study of influenza virus inhibitors. Antivir Res 48:1–16.

    Article  PubMed  CAS  Google Scholar 

  64. Barroso L, Treanor J, Gubareva L, Hayden FG (2005) Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 10:901–910.

    PubMed  CAS  Google Scholar 

  65. BioCryst Pharmaceuticals. (n.d.) Peramvir today. Available at: www.biocryst.com/pdf/peramivirfacts.pdf.

  66. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P (2006) Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir Res 69:39–45.

    Article  PubMed  CAS  Google Scholar 

  67. Arnold E (2006) Intramuscular Peramivir injections promote survival in H5N1 ferret model, Late Breaker Abstracts of 46th ICAAC pp. 5 (Abst. # V-2041b)

    Google Scholar 

  68. Kati WM, Montgomery D, Carrick R, Gubareva L, Maring C, McDaniel K, Steffy K, Molla A, Hayden F, Kempf D, Kohl-brenner W (2002) In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neur-aminidases and influenza virus replication. Antimicrob Agents Chemother 46:1014–1021.

    Article  PubMed  CAS  Google Scholar 

  69. Ison MG, Hayden FG, Mishin V, Braciale TJ, Gubareva L. (2006) Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. Journal of Infect Diseases 193:765–772.

    Article  CAS  Google Scholar 

  70. Macdonald SJF, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GGA, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, mith D, Wu WY, Tucker SP (2004) Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Che-mother 48:4542–4549.

    Article  CAS  Google Scholar 

  71. Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, Kimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY, Tucker SP (2005) Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 48:2964–2971.

    Article  PubMed  CAS  Google Scholar 

  72. Nakai N, Yamamura K, Fukuda K, Kobayashi N, Hirota T (2003) R-118958, a unique anti-influenza agent: Microscopic examination of drug distribution in lung after intranasal administration to mice, Abstracts of 43rd ICAAC pp. 258 (Abst # F-1832)

    Google Scholar 

  73. Yamashita M, Ohno A, Tomozawa T, Yoshida S (2003) R-118958, A unique anti-influenza agent: II. Single administration shows high efficacy for both prophylaxis and treatment. Abstracts of 43rd ICAAC (Abst. # F1830)

    Google Scholar 

  74. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977–981.

    Article  PubMed  CAS  Google Scholar 

  75. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981–986.

    Article  PubMed  CAS  Google Scholar 

  76. Markland W, McQuaid TJ, Jain J, Kwong AD (2000) Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 44:859–866.

    Article  PubMed  CAS  Google Scholar 

  77. Takahashi K, Furuta Y, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Shiraki K (2003) In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 14:235–241.

    PubMed  CAS  Google Scholar 

  78. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong M-H, Morrcy JD, Furuta Y (2007). Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice. Antimicrob Agents Chemother 51(3):845–851.

    Article  PubMed  CAS  Google Scholar 

  79. Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM, Bernstein DI (1987) Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 31:1285–1287.

    PubMed  CAS  Google Scholar 

  80. Hayden FG, Sable CA, Connor JD, Lane J. (1996). Intravenous ribavirin by constant infusion for serious influenza and parain-fluenzavirus infection. Antiviral Therapy 1:51–56.

    PubMed  CAS  Google Scholar 

  81. Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, Johnson G, Van DR, Groothuis JR Arrobio J, et al. (1994) Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 125:129–135.

    Article  PubMed  CAS  Google Scholar 

  82. Wu JZ, Walker H, Lau JY, Hong Z (2003) Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 47:426–431.

    Article  PubMed  CAS  Google Scholar 

  83. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antivir Res 68:10–17.

    Article  PubMed  CAS  Google Scholar 

  84. Lin CC, Yeh LT, Vitarella D, Hong Z (2003) Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 14:145–152.

    PubMed  CAS  Google Scholar 

  85. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 50:1470–1479.

    Article  PubMed  CAS  Google Scholar 

  86. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim DH, Malakhov MP, Yu M, Fang F, Katz JM (2007). DAS181, a novel sialidase fusion protein, protects mice from lethal avain influenza H5N1 virus infection. Journal of Infectious Diseases 196:1493–1499

    Article  PubMed  CAS  Google Scholar 

  87. Gambaryan AS, Boravleva EY, Matrosovich TY, Matrosovich MN, Klenk HD, Moiseeva EV, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV (2005) Polymer-bound 6' sialyl-N-acetyllactosamine protects mice infected by influenza virus. Antivir Res 68:116–123.

    Article  PubMed  CAS  Google Scholar 

  88. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR (2003) Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 47:2518–2525.

    Article  PubMed  Google Scholar 

  89. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S (2006) Inhibition of influenza virus infection by a novel antiviral Peptide that targets viral attachment to cells. J Virol 80:11,960–11,967.

    CAS  Google Scholar 

  90. Kido H, Okumura Y, Yamada H, Le TQ, Yano M (2007). Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Current Pharmaceutical Design 13:403–412.

    Article  Google Scholar 

  91. Zhirnov OP, Ovcharenko AV, Bukrinskaya AG (1985) Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J Gen Virol 66:1633–1638.

    Article  PubMed  CAS  Google Scholar 

  92. Zhirnov OP, Kirzher LS, Ovcharenko AV, Malyshev NA (1996)[Clinical effectiveness of aprotinin aerosol in influenza and parain-fluenza]. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 26–31.

    Google Scholar 

  93. Hosoya M, Matsuyama S, Baba M, Suzuki H, Shigeta S (1992) Effects of protease inhibitors on replication of various myxovi-ruses. Antimicrob Agents Chemother 36:1432–1436.

    PubMed  CAS  Google Scholar 

  94. Ovcharenko AV, Zhirnov OP (1994) Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antivir Res 23:107–118.

    Article  PubMed  CAS  Google Scholar 

  95. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antivir Res 47:57–77.

    Article  PubMed  CAS  Google Scholar 

  96. Hanson B, Boon A, Lim A, Webb A, Ooi E, Webby R (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemaggluti-nin in mice. Respir Res 7:126.

    Article  PubMed  CAS  Google Scholar 

  97. Ramisse F, Deramoudt FX, Szatanik M, Bianchi A, Binder P, Hannoun C, Alonso JM (1998) Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immuno-therapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clin Exp Immunol 111:583–587.

    Article  PubMed  CAS  Google Scholar 

  98. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W (1997) A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin- specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 71:4347–4355.

    PubMed  CAS  Google Scholar 

  99. Okuno Y, Matsumoto K, Isegawa Y, Ueda S (1994) Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68:517–520.

    PubMed  CAS  Google Scholar 

  100. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145: 599–609.

    PubMed  Google Scholar 

  101. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X (2006) Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respiratory Research 7:43.

    Article  PubMed  CAS  Google Scholar 

  102. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 4:e178

    Article  PubMed  CAS  Google Scholar 

  103. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811.

    Article  PubMed  CAS  Google Scholar 

  104. Vaucheret H, Beclin C, Fagard M (2001) Post-transcriptional gene silencing in plants. J Cell Sci 114:3083–3091.

    PubMed  CAS  Google Scholar 

  105. McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3:737–747.

    Article  PubMed  CAS  Google Scholar 

  106. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 100:2718–2723.

    Article  PubMed  CAS  Google Scholar 

  107. Hui EK, Yap EM, An DS, Chen IS, Nayak DP (2004) Inhibition of influenza virus matrix (M1) protein expression and virus replication by U6 promoter-driven and lentivirus- mediated delivery of siRNA. J Gen Virol 85:1877–1884.

    Article  PubMed  CAS  Google Scholar 

  108. Ge Q, Eisen HN, Chen J (2004) Use of siRNAs to prevent and treat influenza virus infection. Virus Res 102:37–42.

    Article  PubMed  CAS  Google Scholar 

  109. McCown M, Diamond MS, Pekosz A (2003) The utility of siRNA transcripts produced by RNA polymerase in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313:514–524.

    Article  PubMed  CAS  Google Scholar 

  110. Tompkins SM, Lo CY, Tumpey TM, Epstein SL (2004) Protection against lethal influenza virus challenge by RNA interference in vivo. PNAS 101:8682–8686.

    Article  PubMed  CAS  Google Scholar 

  111. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. PNAS 101:8676–8681.

    Article  PubMed  CAS  Google Scholar 

  112. Ge Q, Pastey M, Kobasa D, Puthavathana P, Lupfer C, Bestwick RK, Iversen PL, Chen J, Stein DA (2006) Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob Agents Chemother 50:3724–3733.

    Article  PubMed  CAS  Google Scholar 

  113. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JMJ (1986) Prevention of natural colds by contact prophylaxis with intra-nasal alpha 2-interferon. N Engl J Med 314:71–75.

    Article  PubMed  CAS  Google Scholar 

  114. Douglas RM, Moore BW, Miles HB, Davies LM, Graham NM, Ryan P, Worswick DA, Albrecht JK (1986) Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 314:65–70.

    Article  PubMed  CAS  Google Scholar 

  115. Tannock GA, Gillett SM, Gillett RS, Barry RD, Hensley MJ, Herd R, Reid AL, Saunders NA (1988) A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect 101:611–621.

    Article  PubMed  CAS  Google Scholar 

  116. Monto AS, Albrecht JK, chwartz SA (1988) Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. Antimicrob Agents Chemother 32:47–50.

    PubMed  CAS  Google Scholar 

  117. Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM (2000) Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 74:6105–6116.

    Article  PubMed  CAS  Google Scholar 

  118. de J, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, H a DQ, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203–1207.

    Article  CAS  Google Scholar 

  119. Baron S, Isaacs A (1962) Absence of interferon in lungs from fatal cases of influenza. BMJ 1:18–20.

    Article  PubMed  CAS  Google Scholar 

  120. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim Hyun J, Halfmann P, Hatta M, Feldmann F, Ali-monti JB, Fernando L, Li Y, Katze MG, Feldmann H, Kawaoka Y (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319–323.

    Article  PubMed  CAS  Google Scholar 

  121. Hammerbeck DM, Burleson GR, Schuller CJ, Vasilakos J P, Tomai M, Egging E, Cochran FR, Woulfe S, Miller RL (2007) Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antivir Res 73:1–11.

    Article  PubMed  CAS  Google Scholar 

  122. Wong JP, Christoper ME, Salazar AM, Dale RM, Sun LQ, Wang M (2007) Nucleic acid-based antiviral drugs against seasonal and avain influenza viruses. Vaccine 25(16):3175–3178

    Article  PubMed  CAS  Google Scholar 

  123. Cluff CW, Baldridge JR, Stover AG, Evans JT, Johnson DA, Lacy MJ, Clawson VG, Yorgensen VM, Johnson CL, Livesay MT, Hershberg RM, Persing DH (2005) Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immunity 73:3044–3052

    Article  CAS  Google Scholar 

  124. Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Mull-bacher A, Wood J, Clark I (2007) Increased survival after gemfibrizol treatment of severe mouse influenze. Antimicrob Agents Chemother 51(8):2965–2968

    Article  PubMed  CAS  Google Scholar 

  125. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e Sousa C (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314:997–1001.

    Article  PubMed  CAS  Google Scholar 

  126. Hayman A, Comely S, Lackenby A, Hartgroves LCS, Good-bourn S, McCauley JW, Barclay WS (2007) NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response. J Virol 81:2318–2327.

    Article  PubMed  CAS  Google Scholar 

  127. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M Jr Garcia-Sastre A (2007) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81:514–524.

    Article  PubMed  CAS  Google Scholar 

  128. Ludwig S, Pleschka S, Planz O, Wolff T (2006) Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cell Microbiol 8:375–386.

    Article  PubMed  CAS  Google Scholar 

  129. Ludwig S (2007) Exploited defense: how influenza viruses take advantage of antiviral signaling responses. Future Virol 2:91–100.

    Article  CAS  Google Scholar 

  130. Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR, Ludwig S (2001) Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 3:301–305.

    Article  PubMed  CAS  Google Scholar 

  131. Ludwig S, Planz O, Pleschka S, Wolff T (2003) Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Molec Med 9:46–52.

    Article  CAS  Google Scholar 

  132. Lavrov SV, Eremkina EI, Orlova TG, Galegov GA, Soloviev VD, Zhdanov VM (1968) Combined inhibition of influenza virus reproduction in cell culture using Interferon and amanta-dine. Nature 217:856–857.

    Article  PubMed  CAS  Google Scholar 

  133. Hayden FG (1986) Combinations of antiviral agents for treatment of influenza virus infections. J Antimicrob Chemother 18:177–183.

    Article  PubMed  CAS  Google Scholar 

  134. Ong AK, Hayden FG (2007) John F. Enders Lecture 2006: anti-virals for influenza. J Infect Dis 196:181–190.

    Article  PubMed  CAS  Google Scholar 

  135. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG (2000) The neuraminidase inhibitor GS4104 (oselta-mivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antivir Res 48:101–115.

    Article  PubMed  CAS  Google Scholar 

  136. Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neur-aminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48:4855–4863.

    Article  PubMed  CAS  Google Scholar 

  137. Smee DF, Wong MH, Bailey KW, Sidwell RW (2006) Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 17:185–192.

    PubMed  CAS  Google Scholar 

  138. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antivir Res 70:121–131.

    Article  PubMed  CAS  Google Scholar 

  139. Ison MG, Gnann JW Jr Nagy-Agren S, Treanor J, Paya C, Steigbigel R, Elliott M, Weiss HL, Hayden FG (2003) Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8:183–190.

    PubMed  CAS  Google Scholar 

  140. Ilyushina NA, Hoffmann E, Solomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12:363–370.

    PubMed  CAS  Google Scholar 

  141. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Mar Del C, Farrar J, Hien TT, Ozbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist GE, Croisier A, Nagjdaliyev A, Roth C, Thomson G, Zucker H, Oxman AD (2007) WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet 7:21–31.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Nikki Shindo, Global Influenza Program, World Health Organization (WHO) for her helpful comments on the manuscript and for facilitating Dr. Fischer's visit to the WHO. We also thank Drs. Robert Sidwell and Dale Barnard, Utah State University, Logan; John Beigel, National Institutes of Health, Bethesda; Yousuke Furuta, Toyama Pharmaceuticals, Japan; Jane Ryan, Biota, Melbourne; James Alexander, Biocryst, Birmingham, AL; Michael Ossi, GlaxoSmithKline, Research Triangle Park; Jackie Katz, Centers for Disease Control and Prevention, Atlanta, GA for sharing unpublished information. We also thank Diane Ramm, University of Virginia, for assistance in manuscript preparation.

Author information

Authors and Affiliations

  1. Johns Hopkins Hospital, Baltimore, MD

    William A. Fischer II & Frederick Hayden

  2. Global Influenza Program, World Health Organization, Geneva, Switzerland

    William A. Fischer II & Frederick Hayden

  3. University of Virginia, Charlottesville, VA, USA

    William A. Fischer II & Frederick Hayden

Authors
  1. William A. Fischer II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Vassil St. Georgiev PhD Karl A. Western MD John J. McGowan PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this paper

Cite this paper

Fischer, W.A., Hayden, F. (2008). Antivirals for Influenza: Novel Agents and Approaches. In: Georgiev, V.S., Western, K.A., McGowan, J.J. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-569-5_19

Download citation

Publish with us

Policies and ethics

Search

Navigation